Bone Biologics Announces Pricing of $2.0 Million Public Offering

Core Viewpoint - Bone Biologics Corporation has announced a public offering of 781,251 shares of common stock at a price of $2.56 per share, along with warrants to purchase an equal number of shares, aiming to raise approximately $2.0 million for clinical trials and other corporate purposes [1][2]. Group 1: Offering Details - The public offering includes 781,251 shares of common stock and warrants, priced at $2.56 per share, with warrants having an exercise price of $2.43, exercisable immediately and expiring in five years [1][2]. - The expected gross proceeds from the offering are approximately $2.0 million before deducting fees and expenses [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to fund clinical trials, maintain and extend the patent portfolio, and for working capital and other general corporate purposes [2]. Group 3: Company Background - Bone Biologics focuses on regenerative medicine for bone, particularly in spinal fusion procedures, and is developing a bone graft substitute product based on preclinical research of the Nell-1 protein [5].